Company: TAK
Filing Date: 2025-06-02
Form Type: 6-K
Source: 0001395064-25-000071
Chunk: 9

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-02
Form: 6-K
Chunk 9
---
 will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

#### Takeda Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

#### Protagonist Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

#### Protagonist Media Contact
Virginia Amann, Founder/CEO

ENTENTE Network of Companies

+1 833 500 0061 ext 1 virginiaamann@ententeinc.com

Takeda Media Contacts:

#### Japanese Media
Tsuyoshi Tada

tsuyoshi.tada@takeda.com

#### U.S. and International Media
Emy Gruppo emy.gruppo@takeda.com

_____________________________________________________

1. Kuykendall A et al. Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Oral presentation at: American Society of Clinical Oncology (ASCO) Annual Meeting, June 1, 2025. Chicago, IL. LBA3.

2. PROMIS Fatigue Short Form 8a Total T-Score

3. MFSAF v4.0 Total Symptom Score 7